



December 14, 2022

BSE Ltd.  
Phiroze Jeejebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code: 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: Press Release**

Enclosed please find Press Release the Company proposes to issue in relation to acquisition of 'Razel' franchise from Glenmark Pharmaceuticals Limited.

We request you to take the above on record.

Thanking you,

Yours faithfully,

**For J. B. Chemicals & Pharmaceuticals Ltd.**

**Sandeep Phadnis**  
**Vice President - Secretarial**  
**& Company Secretary**

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Energy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



## Press Release

### **JB Pharma to acquire the entire Razel (Rousvastatin) franchise from Glenmark Pharmaceuticals Ltd**

- The acquisition marks JB Pharma's entry into the 'Statin' segment which is the largest group in the cardiac therapy
- Razel ranks among the top 10 brands in the Rousvastatin molecule category in the country

**Mumbai, India; December 14, 2022** – JB Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharmaceutical companies in India, entered into an agreement with Glenmark Pharmaceuticals Ltd to acquire the Razel (Rousvastatin) franchise for the India and Nepal region. The transaction is expected to be closed within next two weeks subject to customary closing formalities.

**Commenting on the acquisition, Mr. Nikhil Chopra, CEO and Whole Time Director, JB Pharma said,** *"We are glad to announce the acquisition of the Razel(Rousvastatin & combinations) franchise from Glenmark Pharmaceuticals, thereby marking JB's expansion into Statins, which is the largest therapeutic segment in cardiology. With this addition, we now have established strong position in statins besides being among the leaders in Hypertension and Heart failure – all the fastest growing therapeutic indications in cardiology."* **He further added** *"We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focussed for this segment and further strengthen our chronic portfolio."*

#####

#### **About JB Pharma**

*J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest-growing pharmaceutical companies in India and a leading player in the hypertension and the heart-failure segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has five brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks among the top 5*

#### **Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

#### **Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

[www.jbpharma.com](http://www.jbpharma.com)



**GOOD PEOPLE**  
*for* **GOOD HEALTH**

---

*manufacturers globally in medicated and herbal lozenges. It has seven state -of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.*

For more details on J.B. Pharma, please visit [www.jbpharma.com](http://www.jbpharma.com)

For details of our latest sustainability report, please visit <https://jbpharma.com/sustainability-report/>

**Media Contact**

Mr. Swadeep Srivastava

Heal Health PR

Tel: +91 93100 87601

Email : [drswadeep@hhconnect.in](mailto:drswadeep@hhconnect.in)

**Investor Contact**

Mr. Sidharth Ragnekar / Ms. Shruti Joshi

CDR India

Tel : +91 976 991 9966/ +91 750 656 7349

Email : [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

[Shruti@cdr-india.com](mailto:Shruti@cdr-india.com)

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



[www.jbpharma.com](http://www.jbpharma.com)